Login
Israel-Hamas Conflict
Airstrike
Military
Parade
War
World Cup
Social Media
Benjamin Netanyahu
Donald Trump
Cricket
Immigration
Motorsports
Artificial Intelligence
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Stemwell Science News image

News from Stemwell Science News

Information about Stemwell Science News

Where is Stemwell Science News located?Stemwell Science News's WebsiteStemwell Science News's Twitter

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Stemwell Science News News

TYBR Health Announces FDA 510(k) Clearance for B3 GEL™ System, a Flowable Bio-Gel to Protect Healing Tissue and Preserve Function
United States · United States

TYBR Health Announces FDA 510(k) Clearance for B3 GEL™ System, a Flowable Bio-Gel to Protect Healing Tissue and Preserve Function

83% Center coverage: 6 sources
/PRNewswire/ -- TYBR Health, a medical device and regenerative medicine company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for...See the Story
Two-Drug GVHD Prophylaxis With Cyclophosphamide Prevails for Stem Cell Transplant

Two-Drug GVHD Prophylaxis With Cyclophosphamide Prevails for Stem Cell Transplant

100% Center coverage: 1 sources
(MedPage Today) -- Patients undergoing matched-donor stem cell transplants lived four times longer without episodes of graft-versus-host disease (GVHD) with post-transplant cyclophosphamide-cyclosporin prophylaxis, a randomized trial showed. Median...See the Story
CRI Announces 2025 Lloyd J. Old STARs: Five Bold Innovators Driving the Future of Cancer Immunotherapy

CRI Announces 2025 Lloyd J. Old STARs: Five Bold Innovators Driving the Future of Cancer Immunotherapy

The Cancer Research Institute (CRI) proudly announces the 2025 class of Lloyd J. Old STARs—five rising scientific leaders poised to reshape cancer immunotherapy through daring, paradigm-shifting research.See the Story

Immunopathogenic Mechanisms and Immunoregulatory Therapies in MASLD

Scientists provide an in-depth discussion of current data related to the immunological mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD) and summarize the effects of current and experimental therapies on immunoregulation in MASLD. [Cellular & Molecular Immunology] Full ArticleDiabetesSee the Story

Patients for Patient Safety in the Context of Rare Diseases

Background: The active involvement of patients and their families in patient safety is essential in healthcare systems. Citizen Science can be useful for this purpose, especially for rare diseases, by gathering data and contributions from patients to design safer environments....See the Story

HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration

HepaRegeniX announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally available small-molecule inhibitor of MKK4, in patients undergoing partial liver resection due to liver metastases deriving from colorectal cancer. [HepaRegeniX (GlobeNewswire)] Press ReleaseRead Article

US FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

AbbVie announced that the US FDA approved a label expansion for MAVYRET®, an oral pangenotypic direct acting antiviral therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis. [AbbVie ] Press ReleaseUnited States · United StatesRead Article

Sequential Drug Release System: Targeting the Tumor ECM for Enhanced Chemotherapy Efficacy

Scientists developed a supramolecular hydrogel, enabling the codelivery and sequential release of hydrophilic and lipophilic drugs designed to target the ECM. [Proceedings of The National Academy of Sciences of The United States of America] AbstractUnited States · United StatesRead Article

MAFB: A Key Regulator of Myeloid Commitment Involved in Hematological Diseases

The authors summarize current knowledge on both physiological and pathological roles of MAFB and highlight the impact of its deregulation on hematological cancer initiation and progression. [Cell Death Discovery] Full ArticleRead Article

Senescence-Resistant Human Mesenchymal Progenitor Cells Counter Aging in Primates

In a 44-week trial, scientists intravenously delivered senescence-resistant human mesenchymal progenitor cells to aged macaques, noting a systemic reduction in aging indicators, such as cellular senescence, chronic inflammation, and tissue degeneration, without any detected adverse effects. [Cell] Full ArticleGraphical AbstractRead Article

Hepatitis B Virus Core Protein Promotes Liver Cancer Progression by Stabilizing CANX and Suppressing IRF7 Transcription

Investigators showed that the expression of calnexin was significantly increased in hepatitis B virus-associated liver cancer, and its upregulation was relevant to the unfavorable survival of patients with the tumor. [Acta Pharmaceutica Sinica B] Full ArticleHepatitis BRead Article

Breaking News Topics Related to Stemwell Science News

United States

United States

Medical

Medical

Science

Science

Cancer

Cancer

Health

Health

News
For You
SearchBlindspotLocal